GetTopicDetailResponse(id=22ab4850622, topicName=帕納替尼, introduction=帕納替尼, content=null, image=null, comments=1, allHits=1598, url=https://h5.medsci.cn/topic?id=48506, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=16599, tagList=[TagDto(tagId=16599, tagName=帕納替尼)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2271634, encodeId=27d322e1634f1, content=<a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細(xì)胞白血病#</a> <a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕納替尼#</a> <a href='/topic/show?id=066211e13968' target=_blank style='color:#2F92EE;'>#貝林妥歐單抗#</a>, objectTitle=JHO：帕納替尼聯(lián)合貝林妥歐單抗一線治療費(fèi)城染色體陽(yáng)性急性淋巴細(xì)胞白血病的復(fù)發(fā)分子特征與預(yù)測(cè)因子研究進(jìn)展, objectType=article, longId=885017, objectId=463888501eb2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PTE4SCK.jpg, objectUrl=/article/show_article.do?id=463888501eb2, replyNumber=0, likeNumber=23, createdTime=2025-07-01, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=463888501eb2, moduleTitle=JHO：帕納替尼聯(lián)合貝林妥歐單抗一線治療費(fèi)城染色體陽(yáng)性急性淋巴細(xì)胞白血病的復(fù)發(fā)分子特征與預(yù)測(cè)因子研究進(jìn)展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=463888501eb2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213457, encodeId=4a39221345eb3, content=<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一線治療#</a> <a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊馬替尼#</a> <a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細(xì)胞白血病#</a> <a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕納替尼#</a>, objectTitle=JAMA：帕納替尼與伊馬替尼在費(fèi)城染色體陽(yáng)性急性淋巴細(xì)胞白血病的一線治療中的比較, objectType=article, longId=833242, objectId=5708833242dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720172627148_92910.jpg, objectUrl=/article/show_article.do?id=5708833242dc, replyNumber=0, likeNumber=117, createdTime=2024-07-05, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5708833242dc, moduleTitle=JAMA：帕納替尼與伊馬替尼在費(fèi)城染色體陽(yáng)性急性淋巴細(xì)胞白血病的一線治療中的比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5708833242dc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1077313, encodeId=279d10e7313ea, content=<a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕納替尼#</a>模型結(jié)果表明，在美國(guó)，達(dá)沙替尼和普納替尼可被視為具有成本效益的選擇，與其他 CML 二線 TKI 相比，可提供臨床益處。, objectTitle=帕納替尼, objectType=topic, longId=48506, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=120, createdTime=2021-12-06, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
